In this video, Dr. Mark Pimentel discusses the pivotal study that validated the biomarkers for IBS (anti-CdtB and anti-vinculin) and led to the creation of the first blood test for Irritable Bowel Syndrome (IBS).
Video Summary:
- There seemed to be a difference between IBS and IBD patients
- ROME Criteria are vague
- 2300 patient study from an FDA approved clinical trial
- The test is highly specific for the detection of IBS-D
- Second generation test produced with epitope optimization
- Ibs-smart has a specificity of over 90%
- Post-test probability with positive results is up to 98%
ibs-smart® could help patients begin appropriate treatment quickly and prevent years of potentially unnecessary procedures like colonoscopies.
At www.ibssmart.com, patients can have an online prescriber evaluate their symptoms and order ibs-smart. Patients can also request kits to take to their current doctor. ([ Ссылка ])
